The role and significance of VEGFR2⁺ regulatory T cells in tumor immunity

References

• FolkmanJTumor angiogenesis: therapeutic implicationsN Engl J Med1971285118211864938153
   PubMed Web of Science ®Google Scholar
• WaldnerMJNeurathMFTargeting the VEGF signaling pathway in cancer therapyExpert Opin Ther Targets20121651322239434
   PubMed Web of Science ®Google Scholar
• ChenMLYanBSLuWCSorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunityInt J Cancer201413431933123818246
   PubMed Web of Science ®Google Scholar
• FinkeJHRiniBIrelandJSunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patientsClin Cancer Res2008146674668218927310
   PubMed Web of Science ®Google Scholar
• HoriSNomuraTSakaquchiSControl of regulatory T cell development by the transcription factor Foxp3Science20032991057106112522256
   PubMed Web of Science ®Google Scholar
• PalomaresOMartínFMLauenerRRegulatory T cells and immune regulation of allergic diseases: roles of IL-10 and TGF-βGenes Immun20141551152025056447
   PubMed Web of Science ®Google Scholar
• SuzukiHOnishiHWadaJVEGFR2 is selectively expressed by Foxp3high CD4+TregEur J Immunol20104019720319902430
   PubMed Web of Science ®Google Scholar
• ErfaniNMehrabadiSMGhayumiMAIncrease of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC)Lung Cancer201277230631122608141
   PubMed Web of Science ®Google Scholar
• LiyanageUKMooreTTJooHGPrevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinomaJ Immunol20021692756276112193750
   PubMed Web of Science ®Google Scholar
• HouFMaDCuiBTreg cells in different forms of uterine cancerClin Chim Acta201341533734023178746
   PubMedGoogle Scholar
• HuJLYangZTangJREffects of gastric cancer cells on the differentiation of Treg cellsAsian Pac J Cancer Prev2013144607461024083711
   PubMedGoogle Scholar
• TakeuchiYNishikawaHRoles of regulatory T cells in cancer immunityInt Immunol201628840140927160722
   PubMed Web of Science ®Google Scholar
• ChaudharyBElkordERegulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targetingVaccines (Basel)201643
   PubMed Web of Science ®Google Scholar
• BruderDProbst-KepperMWestendorfAMNeuropilin-1: a surface marker of regulatory T cellsEur J Immunol200434362363014991591
   PubMed Web of Science ®Google Scholar
• FacciabeneAPengXHagemannISTumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cellsNature2011475735522623021753853
   PubMed Web of Science ®Google Scholar
• OussaNADahmaniAGomisMVEGF requires the receptor NRP-1 to inhibit lipopolysaccharide-dependent dendritic cell maturationJ Immunol2016197103927393527815442
   PubMed Web of Science ®Google Scholar
• TermeMTartourETaiebJVEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancerOncoimmunology201328e2515624083078
   PubMedGoogle Scholar
• FrickeIMirzaNDupontJVascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responsesClin Cancer Res200713164840484817699863
   PubMed Web of Science ®Google Scholar
• HorikawaNAbikoKMatsumuraNExpression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor CellsClin Cancer Res201723258759927401249
   PubMed Web of Science ®Google Scholar
• HuCXJiangXDRole of NRP-1 in VEGF-VEGFR2-independent tumorigenesisTarget Oncol201611450150526916409
   PubMed Web of Science ®Google Scholar
• Ozao-ChoyJMaGKaoJThe novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapiesCancer Res20096962514252219276342
   PubMed Web of Science ®Google Scholar
• YuYWangYYWangYQAntiangiogenic therapy using endostatin increases the number of ALDH+lung cancer stem cells by generating intratumor hypoxiaSci Rep201663423927703219
   PubMed Web of Science ®Google Scholar
• HuoMZhaoYSatterleeABTumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironmentJ Control Release2017245819427863995
   PubMed Web of Science ®Google Scholar
• HodiFSLawrenceDLezcanoCBevacizumab plus ipilimumab in patients with metastatic melanomaCancer Immunol Res20142763264224838938
   PubMed Web of Science ®Google Scholar
• CarvalhoMIPiresIPradaJIntratumoral FoxP3 expression is associated with angiogenesis and prognosis in malignant canine mammary tumorsVet Immunol Immunopathol20161781927496736
   PubMed Web of Science ®Google Scholar
• GavalasNGTsiatasMTsitsilonisOVEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2Br J Cancer2012107111869187523169339
   PubMed Web of Science ®Google Scholar
• MorFQuintanaFJCohenIRAngiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarizationJ Immunol200417274618462315034080
   PubMed Web of Science ®Google Scholar
• ZiogasACGavalasNGTsiatasMVEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2Int J Cancer2012130485786421445972
   PubMed Web of Science ®Google Scholar
• TanakaASakaguchiSRegulatory T cells in cancer immunotherapyCell Res20172710911827995907
   PubMed Web of Science ®Google Scholar
• GarcíaMBellosilloBSánchez-GonzálezBStudy of regulatory T-cells in patients with gastric malt lymphoma: influence on treatment response and outcomePLoS One2012712e5168123284739
   PubMed Web of Science ®Google Scholar
• JinLLiuWRTianMXCCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosisOncotarget2017835135514828042950
   PubMedGoogle Scholar
• KimMSohnMShimMPrognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor-β (PDGF-β), and PDGF-β receptor expression in papillary renal cell carcinomaHum Pathol201761788927989785
   PubMedGoogle Scholar
• KeXZhangSXuJNon-small-cell lung cancer-induced immunosuppression by increased human regulatory T cells via Foxp3 promoter demethylationCancer Immunol Immunother201665558759927000869
   PubMed Web of Science ®Google Scholar
• SuzukiHOnishiHMorisakiTIntratumoral FOXP3+VEGFR2+ regulatory T cells are predictive markers for recurrence and survival in patients with colorectal cancerClin Immunol20131461263323202541
   PubMed Web of Science ®Google Scholar
• GotoHKudoEKariyaRTargeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphomaJ Cancer Res Clin Oncol2015141346547425304617
   PubMed Web of Science ®Google Scholar
• RolandCLLynnKDToombsJECytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancerPLoS One2009411e766919888452
   PubMed Web of Science ®Google Scholar
• DominguesIRinoJDemmersJAVEGFR2 translocates to the nucleus to regulate its own transcriptionPLoS One201169e2566821980525
   PubMedGoogle Scholar
• SchmiedelYMombo-NgomaGLabudaLACD4+CD25hiFOXP3+ regulatory t cells and cytokine responses in human schistosomiasis before and after treatment with praziquantelPLoS Negl Trop Dis201598e000399526291831
   PubMedGoogle Scholar
• OhDSKimHOhJEIntratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responsesOncotarget201718829474404745328537894
   PubMedGoogle Scholar
• SonCHBaeJLeeHREnhancement of antitumor immunity by combination of anti-CTLA-4 antibody and radioimmunotherapy through the suppression of TregsOncol Lett20171353781378628521478
   PubMedGoogle Scholar
• TermeMPernotSMarcheteauEVEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancerCancer Res201373253954923108136
   PubMed Web of Science ®Google Scholar
• ManegoldCDingemansACGrayJEThe potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLCJ Thorac Oncol201712219420727729297
   PubMed Web of Science ®Google Scholar
• KoJSZeaAHRiniBISunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patientsClin Cancer Res20091562148215719276286
   PubMed Web of Science ®Google Scholar
• DesarIMJacobsJHHulsbergen-vandeKaaCASorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patientsInt J Cancer2011129250751220839259
   PubMedGoogle Scholar
• CabreraRAraratMXuYImmune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinomaCancer Immunol Immunother201362473774623223899
   PubMed Web of Science ®Google Scholar
• KobayashiMKuboTKomatsuKChanges in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapyMed Oncol201330255623539200
   PubMed Web of Science ®Google Scholar
• LiJYDuanXFWangLPSelective depletion of regulatory T cells subsets by docetaxel treatment in patients with non-small cell lung cancerJ Immunol Res2014201428617024868562
   PubMed Web of Science ®Google Scholar